Blurbs

Analysts Are Bullish on Top Healthcare Stocks: Cormedix (CRMD), Rocket Pharmaceuticals (RCKT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cormedix (CRMDResearch Report), Rocket Pharmaceuticals (RCKTResearch Report) and Sutro Biopharma (STROResearch Report) with bullish sentiments.

Cormedix (CRMD)

In a report released today, Serge Belanger from Needham maintained a Buy rating on Cormedix, with a price target of $12.00. The company’s shares closed last Monday at $7.52, close to its 52-week high of $8.03.

According to TipRanks.com, Belanger is a 4-star analyst with an average return of 8.8% and a 48.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals.

Currently, the analyst consensus on Cormedix is a Moderate Buy with an average price target of $13.00, implying a 79.3% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $14.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Rocket Pharmaceuticals (RCKT)

Needham analyst Gil Blum maintained a Buy rating on Rocket Pharmaceuticals today and set a price target of $62.00. The company’s shares closed last Monday at $15.84.

According to TipRanks.com, Blum is a 1-star analyst with an average return of -2.1% and a 43.9% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Aeglea Biotherapeutics, and Crispr Therapeutics AG.

Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $53.80, a 236.0% upside from current levels. In a report issued on July 25, Stifel Nicolaus also maintained a Buy rating on the stock with a $56.00 price target.

Sutro Biopharma (STRO)

Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Sutro Biopharma today and set a price target of $26.00. The company’s shares closed last Monday at $6.19, close to its 52-week low of $3.33.

According to TipRanks.com, Shu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.1% and a 27.9% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.

Sutro Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $25.33, which is a 336.7% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CRMD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed